Tislelizumab plus chemotherapy improved survival in advanced oesophageal cancer
In short: A global trial of 649 patients found that tislelizumab plus chemotherapy significantly extended overall survival compared to placebo plus chemotherapy for advanced oesophageal squamous cell carcinoma. The treatment reduced the risk of death by about a third.
This phase 3 trial compared tislelizumab, an anti-PD-1 antibody, with placebo in combination with standard chemotherapy for advanced oesophageal cancer. The study involved 649 patients randomly assigned to either treatment. The main outcome was overall survival, measured in the intention-to-treat population.
The results showed that tislelizumab improved survival, with a median of 17.2 months versus 10.6 months for placebo. However, the study was limited to patients with advanced disease and did not include those who had previously received treatment.
Why it matters: This study shows that tislelizumab plus chemotherapy can improve survival for some patients with advanced oesophageal cancer.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Xu et al. (2023). Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. The Lancet. Oncology.
To cite this card, link to https://intellectplus.co.uk/app/health-research-tislelizumab-plus-chemotherapy-improved-survival-in-advanced.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
